Chief Executive Officer Heather C. Getz of TELA Bio Inc. acquired 12,500 shares of the company’s common stock on August 17, 2026, for a total consideration of $8,311. The transaction was conducted at prices ranging from $0.6504 to $0.6749 per share, with a weighted average price of $0.6649. Following the purchase, Getz’s direct holdings in TELA Bio increased to 532,500 shares.
The company’s shares, listed on the NASDAQ under the ticker TELA, were trading at approximately $0.70 on Tuesday, up roughly 8% over the past week. TELA Bio’s market capitalization stood at $31.43 million as of the latest data.
TELA Bio reported a net loss of 20 cents per share in the second quarter, missing Wall Street’s forecast of a 17-cent loss. Revenue totaled $19.3 million, falling short of the $21.04 million expected by analysts. The company withdrew its full-year 2026 revenue guidance, citing slower-than-anticipated sales-force ramp times and weaker performance in the first half of the year.
Despite the revenue shortfall, TELA Bio’s OviTex unit reported a 12% year-over-year volume increase. However, revenue in the Plastic and Reconstructive Surgery segment declined by 24.7%, weighing on overall sales. Management indicated expectations for a recovery in the second half of the year. Gross margin improved to 72% from 70% in the prior-year period, supported by tariff refunds and reduced inventory charges.
